Osmotica Pharmaceuticals PLC appointed Gregory Cowan to its board of directors and audit committee, effective Jan. 2, 2019.

Cowan previously served as executive vice president and CFO of Avantor Inc.

Bridgewater, N.J.-based Osmoticsa develops specialty products for underserved patient populations. Its products include M-72 for attention deficit hyperactivity disorder and Osmolex ER for Parkinson's and drug-induced extrapyramidal reactions in adults.